Literature DB >> 16418346

Platelet receptors.

Paul Blom, Michael Korona, Lee Haikal.   

Abstract

Mesh:

Substances:

Year:  2006        PMID: 16418346      PMCID: PMC7976080     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


× No keyword cloud information.
  7 in total

Review 1.  Pharmacologic agents in stroke prevention, acute stroke therapy, and interventional procedures.

Authors:  J J Connors
Journal:  J Vasc Interv Radiol       Date:  2004-01       Impact factor: 3.464

2.  Abciximab in patients with ruptured intracranial aneurysms.

Authors:  Richard I Aviv; Richard O'Neill; Maneesh C Patel; Iain R Colquhoun
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

Review 3.  Economic issues in glycoprotein IIb/IIIa receptor therapy.

Authors:  W B Hillegass; A R Newman; D L Raco
Journal:  Am Heart J       Date:  1999-07       Impact factor: 4.749

4.  Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.

Authors:  H Dasgupta; J C Blankenship; G C Wood; C M Frey; S L Demko; F J Menapace
Journal:  Am Heart J       Date:  2000-08       Impact factor: 4.749

5.  Efficacy of abciximab readministration in coronary intervention.

Authors:  M Madan; D J Kereiakes; J B Hermiller; M M Rund; G Tudor; L Anderson; M B McDonald; S D Berkowitz; M H Sketch; H R Phillips; J E Tcheng
Journal:  Am J Cardiol       Date:  2000-02-15       Impact factor: 2.778

Review 6.  Platelet aggregation inhibitors for use in peripheral vascular interventions: what can we learn from the experience in the coronary arteries?

Authors:  Richard Shlansky-Goldberg
Journal:  J Vasc Interv Radiol       Date:  2002-03       Impact factor: 3.464

7.  Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates.

Authors:  Martin Moser; Ulf Bertram; Karlheinz Peter; Christoph Bode; Johannes Ruef
Journal:  J Cardiovasc Pharmacol       Date:  2003-04       Impact factor: 3.105

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.